Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.20
(
-0.14%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.43
(
-2.02%
)
Bitcoin
70,363.09
(
-1.23%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 163194

Saturday, 06/29/2013 1:08:02 PM

Saturday, June 29, 2013 1:08:02 PM

Post# of 257262

GILD/ABBV/ENTA/Medivir/etc—Seeing 90+% SVR rates with the first-generation oral combo from GILD brings into question the long-term utility of the P.I. class.

Respectfully disagree. GILD hasn’t yet produced an oral GT1 regimen that’s even close to being competitive with the 93% SVR rate in null responders observed in ABBV’s AVIATOR study (#msg-80736847).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now